Skip to main content
. 2021 May 26;13(11):2603. doi: 10.3390/cancers13112603
AEs Adverse events
AJCC American Joint Committee on Cancer
CRT Chemoradiotherapy
CT Computed tomography
CTLA-4 Cytotoxic T-lymphocyte-associated antigen 4
EGFR Epidermal growth factor receptor
ESMO European Society of Medical Oncology
ICI Immune checkpoint inhibitors
IV Intravenous
MPR Major pathological response
NCCN National Comprehensive Cancer Network
NSCLC Non small-cell lung cancer
OS Overall survival
pCR Pathological complete response
PD-1 Programmed death 1
PD-L1 Programmed death-ligand 1
PET/CT Positron emission tomography/computed tomography
PFS Progression-free survival
RT Radiation therapy
SUV Standardized uptake values
TKI Tyrosine kinase inhibitors
TMB Tumor mutational burden
TNM Tumor, Node, and Metastasis staging system of American Joint Committee on Cancer